Found 10 matching trials
The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
PHASE2The objective of the study is to evaluate efficacy and safety of two differ...
Location
University Hospital of Antwerp
Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
N/AThis multicenter, open-label, prospective single-arm study will enroll adul...
Location
Chinese PLA General Hospital
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
N/ATo observe of the efficacy and safety of early initiation of budesonide ent...
Location
Sichuan Provincial People's Hospital
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial
PHASE4IgA nephropathy (IgAN) is a chronic progressive kidney disease, and long-te...
Location
Multiple Locations
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
PHASE3The overall aim of the study is to evaluate the efficacy, safety, and toler...
Location
University of Alabama at Birmingham, 1720 2nd Ave South
Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
PHASE3This is a Phase 3b, multicenter, open-label extension (OLE) study to evalua...
Location
Peking University First Hospital
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
PHASE3This is a Phase 3b, multicenter, open-label extension (OLE) study to evalua...
Location
13 Investigator sites
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
PHASE2The study will investigate the effect of PL-56 on albumin leakage and renal...
Location
Linköping University Hospital
Nefecon and Ambrisentan in IgA Nephropathy
PHASE4Application of Budesonide in Combination with Ambrisentan in the treatment ...
Location
The First Hospital of Jilin University
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
PHASE4The goal of this clinical trial is to assess the efficacy and safety of ext...
Location
Univ of Alabama/Birmingham